Form 8-K - Current report:
SEC Accession No. 0001213900-22-046925
Filing Date
2022-08-11
Accepted
2022-08-11 16:45:21
Documents
15
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea164168-8k_citiuspharma.htm   iXBRL 8-K 29493
2 PRESS RELEASE, DATED AUGUST 11, 2022 ea164168ex99-1_citiuspharma.htm EX-99.1 98065
3 GRAPHIC ex99-1_001.jpg GRAPHIC 14478
  Complete submission text file 0001213900-22-046925.txt   376262

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE ctxr-20220811.xsd EX-101.SCH 3681
5 XBRL DEFINITION FILE ctxr-20220811_def.xml EX-101.DEF 26572
6 XBRL LABEL FILE ctxr-20220811_lab.xml EX-101.LAB 36574
7 XBRL PRESENTATION FILE ctxr-20220811_pre.xml EX-101.PRE 25196
9 EXTRACTED XBRL INSTANCE DOCUMENT ea164168-8k_citiuspharma_htm.xml XML 5345
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 221156550
SIC: 2834 Pharmaceutical Preparations